Krista L Lentine1,2,3, Mark A Schnitzler4, Huiling Xiao5,4, Daniel C Brennan6. 1. Center for Outcomes Research, Saint Louis University School of Medicine, St. Louis, MO, USA. lentinek@slu.edu. 2. Abdominal Transplantation, Saint Louis University School of Medicine, St. Louis, MO, USA. lentinek@slu.edu. 3. Saint Louis University, Salus Center 4th Floor, 3545 Lafayette Avenue, St. Louis, MO, 63104, USA. lentinek@slu.edu. 4. Abdominal Transplantation, Saint Louis University School of Medicine, St. Louis, MO, USA. 5. Center for Outcomes Research, Saint Louis University School of Medicine, St. Louis, MO, USA. 6. Transplant Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
After publication of this article, it has come to our attention that a few corrections had not been updated. We are publishing this erratum to highlight what has been updated from the original article. The updates are as follows:-Abstract – the abstract has been updated to reflect the figures in Table 2, patient survival percentage has been updated from 52.5 % to 52.8 %.Table 2 – The P value for Freedom from acute rejection, graft failure or death has been updated from 0.05 to 0.04.Figure 3 captions were incorrect on the original article. This has now been updated. The caption for 3b was updated from Patient survival to Death-censored graft survival. The caption for 3c was updated from Death censored graft survival to Patient Survival.The corresponding text relating to Fig. 3 has also been updated in line with the figure changes. In the original article it was:-Patient survival was numerically and statistically similar in both treatment groups at 5 years and equivalent at 10 years (rATG, 52.8 %; basiliximab, 52.2 %; P = 0.92) (Fig. 3b). Death-censored graft survival was also equivalent in the two groups by 10 years (rATG, 68.5 %; basiliximab, 68.4 %; two-sided P = 0.80) (Fig. 3c). Combining trends in mortality and graft failure, all-cause graft survival was generally similar over time among participants randomized to both trial arms, and by 10 years was 34.3 % in those treated with rATG versus 30.9 % in those treated with basiliximab at (two-sided P = 0.56) (Fig. 3d).This has now been updated to the following:-Death-censored graft survival was also equivalent in the two groups by 10 years (rATG, 68.5 %; basiliximab, 68.4 %; two-sided P = 0.80) (Fig. 3b). Patient survival was numerically and statistically similar in both treatment groups at 5 years and equivalent at 10 years (rATG, 52.8 %; basiliximab, 52.2 %; P = 0.92) (Fig. 3c). Combining trends in mortality and graft failure, all-cause graft survival was generally similar over time among participants randomized to both trial arms, and by 10 years was 34.3 % in those treated with rATG versus 30.9 % in those treated with basiliximab (two-sided P = 0.56) (Fig. 3d).